BofA raised the firm’s price target on DexCom (DXCM) to $90 from $80 and keeps a Buy rating on the shares post the Q3 report. DexCom did a good job instilling confidence in its 2025 revenue target ...
On Monday, DexCom (NASDAQ:DXCM) shares received an optimistic update from Redburn-Atlantic, with analyst Issie Kirby (NYSE:KEX) upgrading the stock from Neutral to Buy and increasing the price target ...
Robert W. Baird analyst Jeff Johnson reiterated a Buy rating on Dexcom (DXCM – Research Report) on January 8 and set a price target of $161.00. Jeff Johnson has given his Buy rating due to a ...
DexCom's improved fundamentals and a 15% lower stock price present a more attractive entry. Learn why DXCM stock is a Buy.
DexCom's growth rate has been accelerating for multiple quarters, and recently came in at around 22%. A rise in GLP-1 drugs has some investors concerned that DexCom's growth opportunities may be ...
Hosted on MSN
Are Wall Street analysts bullish on DexCom’s stock?
California-based DexCom, Inc. (DXCM) is a leading medical technology company specializing in continuous glucose monitoring (CGM) systems for people with diabetes. With a market cap of $22.3 billion, ...
Tim Smith has 20+ years of experience in the financial services industry, both as a writer and as a trader. Shares in Dexcom plunged in extended trading Thursday after the medical devices company ...
They have outpaced the S&P 500 over the past 10 years.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results